Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016', provides in depth analysis on Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) targeted pipeline therapeutics. The report provides comprehensive information on the Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - The report reviews Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects - The report assesses Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) Overview 6 Therapeutics Development 7 Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Products under Development by Stage of Development 7 Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Products under Development by Therapy Area 8 Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Products under Development by Indication 9 Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Products under Development by Companies 12 Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Products under Development by Universities/Institutes 14 Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Companies Involved in Therapeutics Development 22 Cyclacel Pharmaceuticals, Inc. 22 Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Drug Profiles 23 CT-526 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 CYC-065 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 sapacitabine + seliciclib - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small Molecules to Inhibit CDK1, CDK5 and GSK3b for Alzheimer's Disease - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Synthetic Peptide to Inhibit CDK5 for CNS and Metabolic Disorders - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 TFP-5 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Dormant Projects 33 Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Featured News & Press Releases 34 Jun 06, 2016: Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO 34 May 19, 2016: Cyclacel's Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 35 Apr 18, 2016: Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors 36 Dec 14, 2015: Molecular Basis for Development of Cyclacel's CYC065 CDK2/9 Inhibitor in Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium 37 Nov 23, 2015: CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models 38 Nov 09, 2015: Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference 38 Oct 26, 2015: Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference 39 Oct 22, 2015: Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors 40 Sep 17, 2015: Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas 40 Apr 20, 2015: Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Other Anti-Cancer Compounds 41 Mar 20, 2015: Cyclacel's CYC065 Featured in Presentations at the American Association for Cancer Research Annual Meeting 2015 43 Sep 18, 2014: Cyclacel's CYC065 CDK Inhibitor Demonstrates Therapeutic Potential in Acute Leukemias With Mixed Lineage Leukemia (MLL) Rearrangements 43 Sep 10, 2014: Cyclacel Announces Abstract Selected for Presentation at Society of Hematologic Oncology Annual Meeting 44 Apr 09, 2013: Cyclacel Pharma Presents Data On Combination Potential Of Sapacitabine And Seliciclib At AACR Annual Meeting 2013 44 Apr 07, 2013: New Drug Combination Shows Efficacy Against Incurable Solid Tumors And BRCA mutations, Study Finds 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Stage and Mechanism of Action, H1 2016 17 Number of Products by Stage and Route of Administration, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 21 Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 22 Dormant Projects, H1 2016 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
